Professor Haq trained at Guy’s Hospital, Hammersmith and the Royal Brompton Hospitals, Imperial College University, Massachusetts General Hospital, Harvard Medical School, and Tufts University in Boston. Following his medical training, he completed a PhD at Harvard Medical School and Massachusetts General in the field of cell signal transduction. His cutting-edge work has provided insight into how cells communicate and has led to the development of a series of signal effector inhibitors.

He has published over 100 peer-reviewed scientific articles and abstracts in publications including The Journal of Clinical Investigations, Proceedings of the National Academy of Science, Ann Rheum Diseases, Journal of Clinical Investigations, Circulation, Arthritis Research and Therapy, and Nature Medicine. He has received multiple national and international awards, fellowships and honours from the Medical Research Council, Wellcome Trust, Zeneca Pharmaceuticals, American Heart Association, and Heart Failure Society of America.

Professor Haq has coordinated and overseen the successful completion of two important MHRA-registered clinical trials in the UK, one being in late-stage established diffuse systemic sclerosis (SSc) – an often fatal autoimmune disease. His work in the USA led to the award of Orphan Drug Designation by the FDA – reserved for only the rarest of diseases – in the indication of SSc. He has worked closely with PwC and Rothschilds in the past, as part of a biopharma valuation process, and with Vertex Pharmaceuticals.

He has recently been filmed in a production with ITN which focuses on the pandemic problem of Alzheimer’s disease as part of Alzheimer’s Disease International (ADI). He has worked with Saatchi and Saatchi and has published articles in Tatler, Hello Magazine, Bride’s Magazine and the Daily Mail.